Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
|Videos|December 18, 2020
Blueprint
Author(s)Danny Freed
The CEO and founder of Blueprint talks how they are improving the quality of mental health care by putting the proper data infrastructure in place.
Advertisement
Blueprint's goal is more efficient and effective mental health care. How are they doing it? Listen as their CEO and founder, Danny Freed, talks more.
Advertisement
Related to this article
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
Advertisement
Advertisement
Trending on Psychiatric Times
1
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
2
The First Ever Treatment-Resistant Depression Awareness Day
3
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
4
The New, Impending Adult ADHD Guidelines
5